Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.51 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.48 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3505960 | 0.87 | MAOB (0.48) | MAOBSPHK2P4HTMBACE1MAOA | |
| SCHEMBL3503834 | 0.86 | MAOB (0.55) | MAOBPARP10SPHK2P4HTMNR4A2 | |
| SCHEMBL5808067 | 0.80 | SCN9A (0.51) | MAOBPARP10P4HTMBACE1NR4A2 | |
| SCHEMBL3504363 | 0.79 | P4HTM (0.75) | MAOBPARP10P4HTMNR4A2MAOA | |
| SCHEMBL3505966 | 0.78 | MAOB (0.63) | MAOBPARP10SPHK2NR4A2MAOA | |
| SCHEMBL3504894 | 0.78 | P4HTM (0.61) | MAOBPARP10P4HTMBACE1NR4A2 | |
| SCHEMBL12924825 | 0.78 | HPGDS (0.56) | MAOBP4HTMKMT2A | |
| SCHEMBL4424401 | 0.78 | SPHK2 (0.53) | MAOBPARP10SPHK2NR4A2MAOA | |
| SCHEMBL3507099 | 0.76 | CXCR2 (0.56) | MAOBPARP10SPHK2EPHX2 | |
| SCHEMBL12896112 | 0.74 | ACACB (0.45) | MAOBPARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | claimed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | claimed |
| EP-1474394-A1 | PYRIDINEAMIDO DERIVATIVES AS INHIBITORS OF MONOAMINE OXIDASE (MAO-B) | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-10 | — | — | EP | claimed |
| US-6667327-B2 | Pyridine amido derivatives | HOFFMANN-LA ROCHE INC. | 2003-12-23 | — | — | US | claimed |
| US-20030158235-A1 | Pyridine amido derivatives | F.HOFFMAN-LA ROCHE AG (CH) | 2003-08-21 | — | — | US | claimed |
| WO-2003066596-A1 | PYRIDINEAMIDO DERIVATIVES AS INHIBITORS OF MONOAMINE OXIDASE (MAO-B) | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | WO | claimed |
| US-20100247543-A1 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | ORYZON GENOMICS, S.A. (ES) | 2010-09-30 | — | — | US | disclosed |
| EP-2195029-A2 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | Oryzon Genomics SA (ES) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009027349-A2 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | ORYZON GENOMICS SA (ES) | 2009-03-05 | — | — | WO | disclosed |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | disclosed |
| EP-1474394-A1 | PYRIDINEAMIDO DERIVATIVES AS INHIBITORS OF MONOAMINE OXIDASE (MAO-B) | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-10 | — | — | EP | disclosed |
| US-6667327-B2 | Pyridine amido derivatives | HOFFMANN-LA ROCHE INC. | 2003-12-23 | — | — | US | disclosed |
| US-20030158235-A1 | Pyridine amido derivatives | F.HOFFMAN-LA ROCHE AG (CH) | 2003-08-21 | — | — | US | disclosed |
| WO-2003066596-A1 | PYRIDINEAMIDO DERIVATIVES AS INHIBITORS OF MONOAMINE OXIDASE (MAO-B) | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158235-A1 | Pyridine amido derivatives | MAOB, MAOA, XDH | MAOB 1/4885PARP10 663/4885SPHK2 4571/4885 |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | MAOB 1/4885PARP10 833/4885SPHK2 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.